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ABSTRACT: Twelve novel 20-sulfonylamidine derivatives
(9a−9l) of camptothecin (1) were synthesized via a Cu-
catalyzed three-component reaction. They showed similar or
superior cytotoxicity compared with that of irinotecan (3)
against A-549, DU-145, KB, and multidrug-resistant (MDR)
KBvin tumor cell lines. Compound 9a demonstrated better
cytotoxicity against MDR cells compared with that of 1 and 3.
Mechanistically, 9a induced significant DNA damage by
selectively inhibiting Topoisomerase (Topo) I and activating
the ATM/Chk related DNA damage-response pathway. In
xenograft models, 9a demonstrated significant activity without overt adverse effects at 5 and 10 mg/kg, comparable to 3 at 100
mg/kg. Notably, 9a at 300 mg/kg (i.p.) showed no overt toxicity in contrast to 1 (LD50 56.2 mg/kg, i.p.) and 3 (LD50 177.5 mg/
kg, i.p.). Intact 9a inhibited Topo I activity in a cell-free assay in a manner similar to that of 1, confirming that 9a is a new class of
Topo I inhibitor. 20-Sulfonylamidine 1-derivative 9a merits development as an anticancer clinical trial candidate.
■ INTRODUCTION
Camptothecin (CPT, 1, Figure 1) is a naturally occurring
alkaloid with remarkable antitumor effects.1−3 Its antitumor
activity has been ascribed to its ability to interfere with the
catalytic cycle of DNA topoisomerase I (Topo I) by stabilizing
an irreversible drug−enzyme−DNA ternary complex and
preventing the religation of single-strand DNA breaks induced
by Topo I.4,5 Intensive synthetic medicinal chemistry efforts
over the past decades have led to potent 1-derivatives, including
topotecan (2) and irinotecan (3), which are now used clinically
to treat ovarian, small cell lung, and colon cancers. Also, several
derivatives, such as gimatecan (4), CKD-602 (5), and BNP-
1350 (6), are in various stages of preclinical or clinical
development.6−8 Although clinically used 1-derivatives remain a
promising class of antitumor agents, their therapeutic use has
been severely hindered by toxicity issues and delivery problems,
due to poor water solubility, as well as instability of the active
lactone form, due to preferential binding of the opened
carboxylate to serum albumin.9,10
Several approaches, including the development of prodrugs
(conjugates and polymer bound camptothecins), new for-
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mulations (liposomes or microparticulate carriers), and
synthetic lipophilic camptothecins have been explored to
improve the antitumor efficiency of the 1-family.11−13 Most
of these strategies aim to maintain the active closed-lactone
form in the plasma compartment. A free 20-hydroxyl group
favors lactone ring-opening due to the formation of intra-
molecular hydrogen bonding,14 while acylation of this group
should stabilize the closed-lactone moiety.15 Moreover, steric
bulk in the introduced ester moiety can be desirable to impede
hydrolysis of the ester bond by various enzymes, including
carboxylesterases, thereby reducing the toxicity. Indeed, our
own results,16,17 as well as those of others with 20(S)-O-acyl
esters,18,19 20(S)-O-carbonate linked tripeptide conjugates,20
and 20(S)-O-linked glycoconjugates,21 have supported the
importance of esterified 1-derivatives for potent activity.
Esterification of the 20-hydroxyl group also enhances plasma
stability and augments in vivo antitumor activity compared with
those of unmodified 1.
Amidines are well known as important pharmacophores22−25
and widely used in bioactive chemicals and drug molecular
design. Also, the introduction of a sulfonyl group into a
bioactive functional fragment results in significant changes in
the compound’s bioactivity;26,27 thus, sulfonylamidines may be
useful structural motifs for the optimization of bioactive
molecules. Because this group is also quite bulky, it is likely
to sterically prevent large enzymes from easily hydrolyzing a
20(S)-O-acyl ester of 1, which should also reduce the toxicity.
In contrast, SN-38, the compound formed from the hydrolysis
of 3, is quite toxic.28 Given these considerations, we postulated
that the introduction of a sulfonylamidine group at the 20-
position of 1 could lead to improved efficacy and reduced
toxicity as well as optimize the physicochemical properties of a
new 1-related anticancer drug candidate. Therefore, in the
present study, we incorporated the functional fragment
sulfonylamidine into 1 at the C-20 position via a Cu-catalyzed
one pot reaction29 and synthesized a novel series of derivatives
of 1 as potential antitumor agents.
■ RESULTS AND DISCUSSION
Chemistry. As shown in Scheme 1, the 20-hydroxyl group
of 1 was esterified to furnish N-Boc-amino acid derivatives (7)
in suitable yields by a simple modification of the carbodiimide
method using a combination of N,N′-diisopropyl carbodiimide
(DIPC) and 4-dimethylaminopyridine (DMAP). The N-Boc
group of 7 was removed with trifluoroacetic acid (TFA) in
Figure 1. Structures of camptothecin (1), topotecan (2), irinotecan (3), gimatecan (4), CKD-602 (5), and BNP-1350 (6).
Scheme 1. Synthesis of Target Compounds 9a−9la
aReagents and conditions: (i) DIPC/DMAP; (ii) 50% TFA-CH2Cl2; (iii) alkynes/CuI/TsN3/Et3N.
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CH2Cl2 (1:1) to form the key intermediate TFA salts 8.
Subsequently, we applied a highly efficient Cu-catalyzed three-
component coupling reaction,29 in which 8 was reacted with p-
toluenesulfonyl azide and a wide range of alkynes to afford the
desired compounds 9a−l in 35−58% yields. The structures of
the target molecules were characterized from 1H NMR, 13C
NMR, IR, and HR-MS data.
Antiproliferative Activity of New Compounds and
Structure−Activity Relationship. The 12 novel 1-derivatives
9a−l were evaluated for in vitro antiproliferative activity against
four human tumor cell lines, KB (nasopharyngeal), A-549
(lung), DU-145 (prostate), and KBvin (MDR KB subline), by
using a sulforhodamine B colorimetric assay with triplicate
experiments.30 Compounds 1 and 3 were used as controls. The
screening results are shown in Table 1.
All 12 new compounds (9a−l) exhibited significant in vitro
cytotoxic activity against the four tested tumor cell lines, with
IC50 values ranging from 0.026 to 11 μM, indicating that both
the R1 and R2 groups in the 20-sulfonylamidine side chain
might influence the cytotoxic activity of the new 1-derivatives.
The new compounds 9a−l (except 9a against KBvin) were less
potent than 1; however, all of the new derivatives showed
equivalent or superior cytotoxic activity compared with that of
3. Among the newly synthesized derivatives, 9a was the most
potent compound against the four tested tumor cell lines.
Interestingly, 9a also showed greater cytotoxic activity against
KBvin (IC50 0.026 μM) compared with that of 1 and 3 (IC50
0.12 and >20 μM, respectively). The results also revealed that
the A-549 cell line was more sensitive than the other three cell
lines to these compounds, which is consistent with the clinical
behavior of other 1-derivatives.19
Structure−activity relationship (SAR) correlations were also
identified for these new 20-sulfonylamidine derivatives of 1.
When the R2 group was fixed as phenyl and the R1 group in the
sulfonylamidines was varied, hydrogen (9b) and methyl (9d)
gave the best results compared with those of larger alkyl groups
in 9f (isopropyl), 9h (isobutyl), and 9j (sec-butyl). Similar
results were seen in the corresponding derivatives bearing a p-
methoxyphenyl R2 group. For example, against the A-549 cell
line, the rank order of cytotoxic potency was 9a (H) > 9c
(methyl) > 9g (isobutyl) ≥ 9e (isopropyl) ≥ 9i (sec-butyl).
Therefore, small aliphatic chains appear to be the best R1
substituents for greater cytotoxic potency. When the R1 group
was kept constant, and the R2 group was changed from phenyl
to p-methoxyphenyl, the cytotoxic activity often improved (for
example, compare 9b to 9a, 9f to 9e, 9h to 9g, or 9j to 9i
against KBvin). In addition, compound 9l bearing a
hydroxymethyl R2 group displayed comparable (DU-145, KB)
or greater (A-549, KBvin) cytotoxic activity compared to that of
9k with a p-methoxyphenyl R2 group. Compound 9k, which
also has a benzyl R1 group, generally exhibited intermediate
potency between compounds with smaller (9a and 9c) and
larger (9e, 9g, and 9i) alkyl R1 groups. These findings indicated
that the cytotoxic profile of 1-derivatives may be sensitive to the
size and electronic density of the substituents at C-20. On the
basis of these in vitro results, compound 9a was selected for in
vivo evaluation.
Mechanism of Action Studies on 9a. Inhibition of Topo
I Activity by 9a in a Cell-Free System. A 1-derivative with an
esterified 20-hydroxy group is expected to be activated by
digestion with carboxylesterases. To determine whether intact
9a inhibits Topo I, a cell-free Topo I activity assay was
employed using purified recombinant human Topo I (Figure
2A). In this assay, supercoiled plasmid DNA is relaxed and
nicked by recombinant Topo I. Thus, with the vehicle control
or a test compound that has no inhibitory effect on Topo I
activity, relaxed and nicked DNA are found. As seen in Figure
2A, 3, known to be a prodrug of 1, showed the same result
since it cannot be activated in this cell-free system as it is by
carboxylesterases in the cell. In contrast, SN-38, a bioactive
metabolite of 3, inhibited Topo I activity. Notably, we found
that intact 9a inhibited Topo I activity in this cell-free assay in a
manner similar to that of 1 (Figure 2A). We authenticated the
inhibitory effect of 9a against Topo I in a dose-dependent
manner (Figure 2B). Thus, we confirmed that 9a is a new class
of Topo I inhibitor.
Induction of Apoptosis by 9a in Human Tumor Cells.
Because A-549 human lung adenocarcinoma epithelial cells
displayed higher sensitivity than the other tested cancer cell
lines to 9a in the preliminary cytotoxicity profile, A-549 cells
were used in our mechanistic study. Initially, we investigated
morphological cellular changes. After exposure to 9a, A-549
Table 1. In Vitro Cytotoxicity Data for 9a−l against Four Human Tumor Cell Linesa
IC50 (μM)
cmpd A-549 DU-145 KB KBvin
9a 0.031 ± 0.0035 0.050 ± 0.0038 0.14 ± 0.018 0.026 ± 0.013
9b 0.057 ± 0.0039 0.13 ± 0.011 0.18 ± 0.0008 0.10 ± 0.0073
9c 0.089 ± 0.0083 0.14 ± 0.0059 0.91 ± 0.060 0.087 ± 0.0087
9d 0.071 ± 0.0069 0.15 ± 0.022 0.22 ± 0.017 0.096 ± 0.0094
9e 1.0 ± 0.11 1.7 ± 0.14 11 ± 0.48 1.5 ± 0.11
9f 1.3 ± 0.12 2.0 ± 0.25 11 ± 0.28 2.2 ± 0.056
9g 0.95 ± 0.018 1.6 ± 0.096 2.7 ± 0.0083 1.0 ± 0.13
9h 0.89 ± 0.039 1.1 ± 0.016 4.4 ± 0.42 1.8 ± 0.030
9i 1.2 ± 0.066 8.3 ± 0.14 9.6 ± 0.042 1.7 ± 0.16
9j 6.5 ± 0.43 11 ± 0.75 11 ± 1.0 8.2 ± 0.61
9k 0.12 ± 0.010 0.22 ± 0.025 0.85 ± 0.024 0.12 ± 0.0019
9l 0.083 ± 0.010 0.20 ± 0.013 0.31 ± 0.021 0.14 ± 0.0081
1 0.016 ± 0.0005 0.029 ± 0.0025 0.037 ± 0.0031 0.12 ± 0.0091
3 9.5 ± 0.11 9.3 ± 0.61 9.8 ± 0.48 >20
aEach assay was performed in triplicate with duplicated samples, and averaged IC50 (μM) values are expressed with standard deviation (SD). A549,
lung carcinoma; DU-145, hormone-insensitive prostate cancer; KB, originally isolated from epidermoid carcinoma of the nasopharynx; and KBvin,
vincristine-resistant KB subline.
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cells showed apoptotic morphological features, including cell
shrinkage and membrane blebbing (Figure 3A). Apoptosis
induction was further confirmed by double staining with FITC-
annexin V and propidium iodide, showing that 9a treatment
increased the percentage of apoptotic cells (annexin V positive
cell population: vehicle versus 9a, 24 h, 1.1% versus 3.7%, P <
0.01; 48 h, 2.0% versus 34.1%, P < 0.001) (Figure 3B). Western
blot analysis showed that cleaved caspases, the executors of
apoptosis, were formed in response to 9a, including caspase-8,
-9, and -3 (Figure 3C). PARP, a hallmark of apoptosis, was also
activated by 9a (Figure 3C). These data demonstrated that 9a
inhibits A-549 cell growth through apoptosis induction.
Activation of DNA Damage Response Pathway by 9a.
The main effect of 1 is to bind to and stabilize the covalent
Topo I-DNA complex, thus the induction of cell cycle delay in
S phase, preventing DNA ligation and eventually leading to
apoptosis.31 Whether 9a activates the same pathway as 1 in A-
549 cells was examined to demonstrate the mechanism of
action. First, we determined the effect of 9a on cell cycle
distribution using flow cytometry analysis (Figure 4A). As we
expected, treatment with 9a for 24 h resulted in increased cell
populations in S and sub-G1 phases. A Topo I-mediated DNA
cleavage assay was performed to examine whether 9a exhibits
an inhibitory effect on Topo I activity in the cell. The results
showed that 9a inhibited the relaxation of supercoiled DNA,
which is similar to the effect of 1 (Figure 4B). However, both
9a and 1 failed to decatenate kineoplast DNA (kDNA),
whereas etoposide, a known Topo II inhibitor, effectively
blocked the decatenation of kDNA (Figure 4C). Because it has
been shown that 1-Topo I-DNA covalent complexes enhance
the transcription-dependent degradation of Topo I via a 26S
proteasome pathway,32 the effects of 9a on the expression levels
of Topo I and Topo II were investigated. Western blot analysis
showed that 9a significantly inhibited protein levels of Topo I
after 8 h of treatment and slightly affected levels of Topo IIα
and Topo IIβ after 24 h treatment (Figure 4D). These results
Figure 2. Compound 9a directly inhibits Topo I in a cell-free system.
(A) Recombinant human Topo I was incubated with the vehicle
(CTL), 100 nM 9a, 100 nM 1 (CPT), or 1 μM 3 (Irinotecan)
followed by incubation with supercoiled plasmid DNA. Plasmid DNA
was separated by agarose gel and stained with ethidium bromide. SN-
38 (100 nM), an active metabolite of 3, was used as a positive control.
(B) Dose-dependent inhibition of Topo I by 9a. Recombinant human
Topo I was incubated with supercoiled plasmid DNA in the presence
of different concentrations of 9a as indicated. These results show that
9a directly inhibits recombinant human Topo I in a dose−response
manner.
Figure 3. Induction of apoptosis by 9a. (A) Compound 9a induced apoptotic morphological alternation. A-549 cells were incubated in the absence
or presence of 100 nM 9a for 24 or 48 h. Morphological changes were observed under a phase-contrast microscope. (B) Compound 9a induces
apoptosis. A-549 cells were treated with the vehicle (CTL) or 100 nM 9a for 24 or 48 h followed by FITC-annexin V with propidium iodide double
staining. Percentages of apoptotic cells were analyzed by flow cytometry. (C) Compound 9a activates caspases. A-549 cells were treated with 100 nM
9a at indicated times. Cells were harvested and lysed for the determination of caspase cleavage using Western blot analysis.
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clearly demonstrated that 9a inhibited Topo I without
interfering with Topo II activity. Compound 9a acts directly
on Topo I and results in the accumulation of covalent Topo I-
DNA complexes followed by proteasomal Topo I degradation,
which is the same effect as 1, and contributes to 9a’s
cytotoxicity.
Compound 1 can induce DNA damage and activate the
ATM-Chk2 DNA damage-response pathway to trigger
apoptotic pathways in cancer cells.33 We found that ATM
underwent phosphorylation at the Ser1981 residue after 0.5 h
treatment with 9a (Figure 4E). Activation of ATM kinase was
confirmed by detecting the phosphorylation of downstream
effectors, Chk1, Chk2, and histone H2AX (Figure 4E).
Phosphorylation of H2AX at the Ser139 residue (γH2AX)
indicated that 9a caused DNA double-strand breaks. P53 plays
a critical role in DNA-damage functions, including cell cycle
regulation and apoptosis triggering.34 The up-regulation and
phosphorylation of p53 were greatly enhanced by 9a (Figure
4E). P53 downstream apoptotic proteins such as PUMA and
BAX were also predominantly increased by 9a. Furthermore, 9a
Figure 4. Mechanisms of action of 9a. (A) Accumulation of S phase by 9a. Cell cycle distribution of A-549 was analyzed by a flow cytometer after
treatment with 0 (CTL), 30, 100, or 300 nM 9a for 24 h followed by staining with propidium iodide. **, P < 0.01. (B) Inhibition of Topo I activity
by 9a in vitro. A-549 cells were treated with the vehicle (CTL), 9a (30, 100 nM), or 1 (30, 100 nM) for 1 h. Cells were harvested for Topo I activity
assay as described in Experimental Section. (C) Selective inhibition of Topo I by 9a. A-549 cells were treated with 9a (100 nM), 1 (100 nM), or
Topo II inhibitor etoposide (30 μM) for 1 h, followed by the Topo II activity assay. (D) Depression of Topo I expression by 9a. A-549 cells were
treated with vehicle (CTL) or 100 nM 9a for the indicated hours. Whole cell lysates were analyzed by Western blotting using antibodies to Topo I,
Topo IIα, Topo IIβ, and β-actin as a loading control. These results demonstrated that compound 9a selectively inhibited Topo I activity and
expression. (E) Activation of DNA damage checkpoint proteins by 9a. Whole cell extracts were prepared from A-549 cells treated with 100 nM 9a or
100 nM 1 for the indicated hours. Phosphorylation of DNA damage checkpoint proteins were detected by Western blotting using specific antibodies
to phosphorylated ATM (p-ATM), ATR (p-ATR), Chk1 (p-Chk1), Chk2 (p-Chk2), p-H2AX, and p53 (p-p53) as indicated. Total amount of each
protein and β-actin was detected by the pan antibody to each protein as the loading control. (F) Activation of apoptosis pathway by 9a. Whole cell
lysates were prepared from A-549 cells treated with 100 nM 9a or vehicle (CTL) for the indicated hours followed by detection of apoptosis-related
proteins as indicated. (G) Schematic representation of the mechanisms of action of 9a. Compound 9a (YQL-9a) directly inhibits Topo I enzymatic
activity and depresses Topo I expression, which results in DNA damage checkpoint activation, cell cycle delay at S phase, and subsequently apoptosis
pathway stimulation.
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up-regulated FADD, a component of death receptor-mediated
extrinsic apoptosis, and down-regulated the pro-survival
proteins Bcl-xL and Bcl-2 by preventing leakage of mitochon-
drial damage contents (Figure 4F).
Taken together, compound 9a (YQL-9a) directly inhibits
Topo I activity and depresses Topo I expression, which induces
cell cycle delay at S phase as well as activation of the DNA
damage-response pathway, and subsequently activates the
apoptosis pathway (Figure 4G). Our data support the
superiority of 9a over parent compound 1, suggesting that 9a
is an excellent potential anticancer drug candidate. Therefore,
we further investigated the antitumor activity of 9a and
toxicological evaluation in vivo.
Antitumor Activity of 9a in Vivo. Xenograft model
antitumor assay using human colorectal adenocarcinoma cell
line HCT116 was performed according to the regimen in Table
2. The 31-day study utilized four groups of mice (n = 8)
bearing established HCT116 xenograft with mean volumes of
approximately 200 mm3 on day one. The tumor growth and
animal body weight change for each treatment group were
measured three times per week (Figure 5). Compound 9a was
administered intravenously (i.v.) for 7 days and then intra-
peritoneally (i.p.) at 5 and 10 mg/kg once every day (QD) to
the end. Two of eight and three of eight mice showed complete
regression in the 5 mg/kg and 10 mg/kg dose groups,
respectively. There were no significant changes in body weight
at either dose. The experimental control using 3 also exhibited
antitumor activity at a dose of 100 mg/kg once every week
(QWK) (P < 0.001), and three mice showed complete
regression, supporting the accuracy of our in vivo evaluation.
On the basis of the Student’s t-test evaluation, 9a at 5 mg/kg (P
< 0.01) and 10 mg/kg (P < 0.001) exhibited significant
antitumor activity in vivo without overt signs of symptoms and
an anaphylactic reaction.
Toxicological Evaluation of 9a in Mice. Acute toxicity of 9a
in the mouse was evaluated pathologically. Sixty 8-week-old
male BALB/c mice were randomized into six groups (n = 10)
to receive 0 (vehicle only), 30, 100, 200, or 300 mg/kg of 9a i.p.
on day zero. One group was kept without treatment as a normal
control. All treated animals showed no anaphylactic responses,
allergic reactions, or significant body weight loss (Figure 6A)
and were as healthy as the normal control animals, indicating
significantly reduced toxicity compared with that of 1 (LD50 =
56.2 mg/kg, i.p.) and 3 (LD50 = 177.5 mg/kg, i.p.).
35 At the
end of the experimental period, all animals were euthanized,
and tissues from the liver, lung, kidney, and spleen were
evaluated histopathologically according to the guidelines
described by Shackelford et al.36 as well as being graded for
symptomatic lesions. Histopathological evaluations included
(1) glycogen deposition, inflammatory cell infiltration, and
focal necrosis in the liver (Figure 6B), (2) regeneration of renal
tubule, inflammatory cell infiltration, and chronic progressive
nephropathy in kidney, and (3) inflammatory cell infiltration
and adenoma in the lung (Figure 6C). Although a few
microscopic lesions were observed in tissues from both 9a-
treated and untreated mice, all lesions were considered
spontaneous lesions and were not related to the administration
of 9a. Thus, 9a-treated animals showed no adverse effects
according to hepatic, splenic, kidney, and lung parameters.
Thus, the animals apparently tolerated treatment with 300 mg/
kg of 9a, portending an acceptable safety profile.
We postulate that the toxicological improvement against
normal tissues might be associated with the introduction of a
sulfonylamidine side chain at the 20-position of 1. Surprisingly,
this modification does not disrupt the inhibitory effect against
Topo I and may also prevent lactone ring-opening resulting in
stabilization of the closed lactone moiety and contributing to
Table 2. Study Design of the Xenograft Model Antitumor
Assaya
treatment regimen
group n agent mg/kg schedule
1 8 vehicle QD
2 8 9a 5 QD
3 8 9a 10 QD
4 8 3 100 QWK
aSaline containing 5% DMSO and 5% cremophor were used as the
vehicle. QD, once every day. QWK, once every week.
Figure 5. Potent antitumor activity of 9a in vivo. A xenograft model antitumor assay was performed using human colorectal HCT116 cells. When the
tumor graft volume reached about 200 mm3, mice were randomly separated into four groups (n = 8), and administration of compound was started
according to the treatment regimen as shown in Table 2 (left panel). Compound 9a (YQL-9a) potently prevented tumor growth at 5 or 10 mg/kg
compared with the vehicle (control), without significant effect on body weight (right panel). Furthermore, two or three mice administered 9a at 5 or
10 mg/kg, respectively, underwent complete regression (CR). Compound 3 (irinotecan) was used as an experimental control, and three mice
displayed CR. These results were statistically significant (P < 0.01, Student’s t-test).
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better bioactivity of 1. Further studies including metabolic and
pharmacokinetic evaluations, as well as introduction of a
sulfonylamidine side chain at the C-7 position of 1, are
currently underway to address this supposition.
■ CONCLUSIONS
In summary, a novel series of 20(S)-sulfonylamidine 1-
derivatives were designed and synthesized with a key step
being a Cu-catalyzed one pot reaction. All 12 derivatives
showed comparable or superior cytotoxic activity compared
with that of 3. Notably, compound 9a was as potent as 1 and
far more potent than 3 against multidrug-resistant KBvin cells.
The IC50 values of the new derivatives ranged from 0.026 to 11
μM, indicating that the R1 and R2 groups in the 20-
sulfonylamidine side chain could greatly influence the cytotoxic
activity of the new 1-derivatives, leading to important SAR
information. Also, 9a at 5 mg/kg and 10 mg/kg demonstrated
significant antitumor activity in mice bearing established human
HCT116 colorectal adenocarcinoma with no significant
changes in body weight at all doses tested. In addition, two
of eight and three of eight mice showed complete regression in
the 5 mg/kg and 10 mg/kg dose groups, respectively.
Histopathological evaluation of acute toxicity against the liver,
spleen, lung, and kidney in mice showed no adverse effects of
9a treatment with 300 mg/kg. On the basis of these positive
results, further development of 9a-related compounds as
potential anticancer clinical trial candidates is definitely
warranted.
■ EXPERIMENTAL SECTION
Chemistry General Information. N-Boc-amino acids and TFA
were purchased from GL Biochem (Shanghai) Company. DIPC and
DMAP were purchased from Sigma Chemical Company (China).
Other reagents and solvents were purchased from commercial sources
and were used as received. The starting compound 1 was isolated from
the Chinese medicinal plant C. acuminata and was purified before
being used (>98% pure). Analytical thin-layer chromatography (TLC)
and preparative thin-layer chromatography (PTLC) were performed
with silica gel plates using silica gel 60 GF254 (Qingdao Haiyang
Chemical Co., Ltd.). Melting points were taken on a Kofler melting
point apparatus and are uncorrected. IR spectra were obtained on an
NIC-5DX spectrophotometer. MS analyses were performed on ZAB-
HS and Bruker Daltonics APEXII49e instruments. NMR spectra were
recorded on a Bruker AM-400 spectrometer at 400 MHz using TMS
as reference (Bruker Company, USA). The purity of all tested
compounds was determined by HPLC (Agilent Technologies 1100
series) equipped with a C-18 bound-phase column (Eclipse Plus C18,
5 μM particle size, 4.6 mm × 250 mm). A gradient elution was
performed with MeOH and water as a mobile phase and was
monitored at 254 nm. All tested compounds were >95% pure.
Figure 6. Pathological evaluation of toxicity of 9a in mice. (A) No significant effect on body weight. Sixty BALB/c mice were randomly divided into
six groups, and 10 animals in each group received an i.p. injection of 9a at 0 (vehicle), 30, 100, 200, or 300 mg/kg, or did not receive an injection at
all (normal). (B) Histopathological examination of hepatotoxicity. Formalin-fixed livers from animals without (normal) or with injection of vehicle,
100 mg/kg 9a or 300 mg/kg 9a, were embedded in paraffin. Tissue sections were stained with hematoxyline and eosin (H&E). Stained sections were
evaluated histopathologically for glycogen deposition, focal necrosis, and inflammatory cell infiltration. Central vein (C) and portal tract (P) were
indicated (upper left panel). Post-mortem change was labeled (*). (C) Summary of histopathological evaluation of toxicity. Tissues from the liver,
spleen, kidney, and lung were fixed with formalin and embedded in paraffin. Tissue sections were evaluated histopathologically as indicated after
staining with H&E. These results demonstrated that the body weight, liver, spleen, kidney, and lung were not affected by treatment with 9a, even at
300 mg/kg.
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Synthesis of Key Intermediates 7 and 8. The appropriate N-
Boc-amino acid (3.13 mmol) was dissolved in 200 mL of anhydrous
CH2Cl2 at rt. To this solution, DIPC (0.5 mL, 3.13 mmol), DMAP
(3.13 mmol), and 1 (3.13 mmol) were added at 0 °C.16 The reaction
mixture was allowed to warm to rt and left for 16 h. The solution was
then washed with 0.1 N HCl, dried, and evaporated under reduced
pressure to yield a white solid, which was recrystallized from MeOH to
give a N-Boc-amino acid 1 ester derivative (7) in 56−87% yield.
Subsequently, this intermediate (7, 1 mmol) was dissolved in a mixture
of CH2Cl2 (10 mL) and TFA (10 mL) and stirred at rt for 1 h. The
solvent was removed, and the remaining solid was recrystallized from
CH2Cl2 and diethyl ether to give the corresponding TFA salt (8) in
57−82% yield.
General Synthetic Procedure for Compounds 9a−91.
Triethylamine (1.2 mmol) was added slowly to a suspension of the
TFA salt 8 (0.5 mmol) in CH2Cl2 (35 mL), and this mixture was
stirred for 10 min until a clear solution was obtained. Under an N2
atmosphere, alkyne (0.5 mmol), p-toluenesulfonyl azide (0.6 mmol),
and CuI (0.05 mmol) were added. The reaction mixture was stirred for
2−6 h at rt. After the reaction was completed, as monitored by TLC,
the reaction mixture was diluted by adding CH2Cl2 (4 mL) and
aqueous NH4Cl solution (6 mL). The mixture was stirred for an
additional 30 min, and two layers were separated. The aqueous layer
was extracted with CH2Cl2 (3 mL × 3). The combined organic layers
were dried over MgSO4, filtered, and concentrated in vacuo. The crude
residue was purified by flash column chromatography on Si gel using
CHCl3−MeOH (10:1−20:1) as eluent to give 9a−9l. HPCL
chromatograms and conditions for all 12 new compounds (9a−9l)
are provided as Supporting Information.
Compound 9a. Yield 52%; mp 129−131 °C; tR-HPLC, 3.59 min
(95.4%). IR (KBr) ν cm−1: 3376, 3285, 2932, 1753, 1663, 1612, 1510,
1455, 1401, 1277, 1249, 1144, 1089, 1053, 892, 789, 688, 553; 1H
NMR (CDCl3, 400 MHz) δ 8.39 (s, 1H, C7−H), 8.24 (d, 1H, J = 8.8
Hz, C9−H), 7.94 (d, 1H, J = 8.0 Hz, C12−H), 7.85 (t, 1H, J = 7.6 Hz,
C11−H), 7.82 (d, 2H, J = 8.0 Hz, Ts-H), 7.68 (t, 1H, C10−H), 7.32
(s, 1H, C14−H), 7.24 (d, 2H, J = 8.0 Hz, Ts-H), 7.04 (d, 2H, J = 8.4
Hz, -PhOCH3), 6.83 (d, 2H, J = 8.8 Hz, -PhOCH3), 5.52 (ABq, 2H, J
= 17.2, C17−H), 5.26 (s, 2H, C5−H), 4.17−4.31 (m, 4H, C23, 30-H),
3.73 (s, 3H, -PhOCH3), 2.39 (s, 3H, Ts-CH3), 2.11−2.21 (m, 2H,
C18−H), 0.91 (m, 3H, C19−H); 13C NMR (100 MHz, CDCl3) δ
167.6, 167.1, 166.8, 159.4, 157.1, 152.2, 148.9, 146.7, 144.8, 131.3,
131.2, 130.8, 129.7, 129.2, 128,4, 128.2, 126.5, 142.4, 140.2, 120.1,
114.9, 95.6, 76.7, 67.2, 55.2, 50.0, 43.3, 38.5, 31.8, 21.5, 7.5. HRMS
calcd for C38H34N4O8S: 729.1990 [M + Na]
+; found, 729.2002 [M +
Na]+.
Compound 9b. Yield 54%; mp132−134 °C; tR-HPLC, 3.33 min
(100%). IR (KBr) ν cm−1: 3394, 3339, 3061, 2973, 2926, 1753, 1663,
1614, 1557, 1498, 1453, 1401, 1278, 1232, 1145, 1089, 1054, 985, 813;
1H NMR (CDCl3, 400 MHz) δ 8.39 (s, 1H, C7−H), 8.24 (d, 1H, J =
8.8 Hz, C9−H), 7.94 (d, 1H, J = 8.0 Hz, C12−H), 7.82−7.86 (m, 3H,
C11−H, Ts-H), 7.68 (t, 1H, C10−H),7.33 (s, 1H, C14−H), 7.28−
7.32 (m, 3H, Ph-H), 7.23 (d, 2H, J = 8.0 Hz, Ts-H), 7.18 (d, 2H, J =
8.0 Hz, Ph-H), 5.51 (ABq, 2H, J = 17.2 Hz, C17−H), 5.26 (s, 2H,
C5−H), 4.20−4.31 (m, 4H, C23, 30-H), 2.39 (s, 3H, Ts-CH3), 2.11−
2.22 (m, 2H, C18−H), 0.91 (m, 3H, C19−H); 13C NMR (100 MHz,
CDCl3) δ 167.6, 166.8, 166.5, 157.2, 152.2, 148.9, 146.4, 144.8, 132.3,
131.2, 130.8, 130.1, 129.7, 129,5, 128.3, 126.5, 142.4, 140.2, 120.2,
95.6, 76.2, 67.2, 50.0, 43.3, 39.3, 31.7, 21.5, 7.5. HRMS calcd for
C37H32N4O7S: 677.2064 [M + Na]
+; found, 677.2051 [M + Na]+.
Compound 9c. Yield 55%; mp 112−114 °C; tR-HPLC, 2.92 min
(96.9%). IR (KBr) ν cm−1: 3371, 3261, 2931, 1751, 1662, 1611, 1548,
1402, 1277, 1249, 1144, 1085, 814, 759, 689; 1H NMR (CDCl3, 400
MHz) δ 8.38 (s, 1H, C7−H), 8.26 (d, 1H, J= 8.8 Hz, C9−H), 7.93 (d,
1H, J = 8.0 Hz, C12−H), 7.80−7.83 (m, 3H, C11−H, Ts-H), 7.67 (t,
1H, C10−H), 7.36 (s, 1H, C14−H), 7.22 (d, 2H, J = 8.0 Hz, Ts-H),
7.02 (d, J = 8.8 Hz, -PhOCH3), 6.81 (d, 2H, J = 8.8 Hz, -PhOCH3),
5.50 (ABq, 2H, J = 17.2 Hz, C17−H), 5.26 (s, 2H, C5−H), 4.86 (m,
1H, C23−H), 4.23 (s, 2H, C30−H), 3.74 (s, 3H, -PhOCH3), 2.39 (s,
3H, Ts-CH3), 2.11−2.21 (m, 2H, C18−H), 1.47 (m, 3H, L-alanine-
CH3), 0.91 (m, 3H, C19−H); 13C NMR (100 MHz, CDCl3) δ 170.8,
166.8, 166.3, 159.4, 157.2, 152.1, 148.9, 146.6, 144.7, 131.4, 131.1,
130.7, 130.5, 129.8, 129.5, 129.1, 128.4, 128.2, 128.0, 126.4, 124.3,
142.2, 140.3, 120.8, 114.8, 95.5, 67.2, 55.2, 50.0, 49.7, 38.6, 31.7, 21.5,
17.4, 7.5. HRMS calcd for C39H36N4O8S: 743.2146 [M + Na]
+; found,
743.2157[M + Na]+.
Compound 9d. Yield 57%, 108−110 °C; tR-HPLC, 3.55 min
(100%). IR (KBr) ν cm−1: 3395, 3311, 2979, 1755, 1667, 1619, 1541,
1402, 1277, 1231, 1143, 1085, 1058, 813, 755, 702; 1H NMR (CDCl3,
400 MHz) δ 8.39 (s, 1H, C7−H), 8.22 (d, 1H, J = 8.4 Hz, C9−H),
7.94 (d, 1H, J = 8.0 Hz, C12−H), 7.80−7.89 (m, 3H, C11−H, Ts-H),
7.69 (t, 1H, C10−H), 7.38−7.41 (m, 2H, Ph-H), 7.36 (s, 1H, C14−
H), 7.30−7.33 (m, 3H, Ph-H), 7.25 (d, 2H, J = 8.0 Hz, Ts-H), 5.51
(ABq, 2H, J = 17.2 Hz, C17−H), 5.25 (s, 2H, C5−H), 4.82 (m, 1H,
C-23H), 4.33 (s, 2H, C30−H), 2.40 (s, 3H, Ts-CH3), 2.11−2.21 (m,
2H, C18−H), 1.44 (d, 3H, L-alanine-CH3), 0.89 (m, 3H, C19−H);
13C NMR (100 MHz, CDCl3) δ 170.0, 166.7, 165.7, 157.2, 152.2,
148.9, 146.7, 144.6, 132.6, 131.1, 130.7, 130.2, 129.8, 129.5, 129.4,
129.2, 128.4, 128.2, 128.1, 126.4, 142.2, 140.2, 120.2, 95.3, 67.2, 50.0,
49.9, 39.5, 31.7, 21.5, 17.3, 7.5. HRMS calcd for C38H34N4O7S:
691.2221[M + H]+; found, 691.2206 [M + H]+.
Compound 9e. Yield 55%; mp 118−120 °C; tR-HPLC, 4.40 min
(95.2%). IR (KBr) ν cm−1: 3392, 3259, 2931, 1749, 1665, 1615, 1541,
1511, 1401, 1277, 1249, 1142, 1086, 812, 689, 553; 1H NMR (CDCl3,
400 MHz) δ 8.38 (s, 1H, C7−H), 8.20 (d, 1H, J= 8.8 Hz, C9−H),
7.94 (d, 1H, J = 8.0 Hz, C12−H), 7.82 (t, 1H, C11−H), 7.72 (d, 2H, J
= 8.4 Hz, Ts-H), 7.66 (t, 1H, C10−H), 7.42 (d, 2H, J = 8.4 Hz,
-PhOCH3), 7.36 (s, 1H, C14−H), 7.17 (d, 2H, J = 8.0 Hz, Ts-H), 7.04
(d, 2H, J = 8.8 Hz, -PhOCH3), 5.51 (ABq, 2H, J = 17.6 Hz, C17−H),
5.26 (s, 2H, C5−H), 4.61 (m, 1H, C23−H), 4.33 (s, 2H, C30−H),
3.80 (s, 3H, -PhOCH3), 2.36 (s, 3H, Ts-CH3), 2.18−2.20 (m, 3H,
C18−H, L-valine-CH(CH3)2), 0.91 (m, 3H, C19−H), 0.74−0.89 (m,
6H, L-valine−CH(CH3)2); 13C NMR (100 MHz, CDCl3) δ 168.4,
166.9, 166.6, 159.6,157.2, 152.2, 148.9, 146.7, 144.1, 131.7, 131.0,
130.6, 129.8, 129.0, 128.4, 128.3, 128.1, 128.0, 126.2, 142.2, 140.2,
120.8, 115.1, 95.5, 76.3, 67.4, 59.2, 55.3, 50.1, 38.8, 31.7, 31.0, 21.4,
17.7, 7.5. HRMS calcd for C41H40N4O8S: 749.2640 [M + H]
+; found,
749.2648 [M + H]+.
Compound 9f. Yield 53%; mp 112−114 °C; tR-HPLC, 4.53 min
(95.1%). IR (KBr) ν cm−1: 3399, 3263, 2964, 1752, 1666, 1620, 1561,
1534, 1455, 14399, 1277, 1256, 1141, 1085, 992, 806; 1H NMR
(CDCl3, 400 MHz) δ 8.38(s, 1H, C7−H), 8.20 (d, 1H, J= 8.8 Hz,
C9−H), 7.93 (d, 1H, J = 8.0 Hz, C12−H), 7.80 (t, 1H, C11−H), 7.73
(d, 2H, Ts-H), 7.66 (t, 1H, C10−H), 7.48−7.53 (m, 5H, Ph-H), 7.36
(s, 1H, C14−H), 7.16 (d, 2H, J = 8.0 Hz,Ts-H), 5.51 (ABq, 2H, J =
17.2 Hz, C17−H), 5.26 (s, 2H, C5−H), 4.60 (m, 1H, C23−H), 4.23
(s, 2H, C30−H), 2.35 (s, 3H, Ts-CH3), 2.18−2.20 (m, 3H, C18−H, L-
valine-CH(CH3)2), 0.91(m, 3H, C19−H), 0.74−0.89 (m, 6H, L-
valine−CH(CH3)2); 13C NMR (100 MHz, CDCl3) δ 168.4, 166.6,
166.3, 157.2, 152.1, 148.9, 146.6, 144.1, 133.0, 131.0, 130.6, 130.4,
129.8, 129.3, 129.0, 128.4, 128.3, 128.0, 126.4, 140.3, 120.8, 95.5, 67.3,
59.1, 50.0, 39.6, 31.7, 31.0, 21.4, 17.5, 7.4. HRMS calcd for
C40H38N4O7S: 719.2534 [M + H]
+; found, 719.2517 [M + H]+.
Compound 9g. Yield 54%; mp 130−132 °C; tR-HPLC, 3.78 min
(96.2%). IR (KBr) ν cm−1: 3343, 3262, 2966, 2930, 1750, 1660, 1615,
1558, 1459, 1278, 1248, 1148, 1088, 814, 687; 1H NMR (CDCl3, 400
MHz) δ 8.38 (s, 1H, C7−H), 8.22 (d, 1H, J = 8.4 Hz, C12−H), 7.92
(d, 1H, J = 8.0 Hz, C9−H), 7.82 (t, 1H, C11−H), 7.75 (d, 1H, J = 8.0
Hz, C11−H), 7.65 (t, 1H, C10−H), 7.30 (d, 2H, J = 8.0 Hz, Ts-H),
7.25 (s, 1H, C14−H), 7.02 (d, 2H, J = 8.8 Hz, -PhOCH3), 6.77 (d,
2H, J = 8.8 Hz, -PhOCH3), 5.32 (Abq, 2H, J = 17.6 Hz, C17−H), 5.22
(s, 2H, C5−H), 4.24−4.29 (m, 3H, C23,C30−H), 3.74 (s, 3H,
-PhOCH3), 2.42 (s, 3H, Ts-CH3), 2.33 (m, 3H, C18−H, L-leucine-
CH2CH(CH3)2), 1.20 (m, 1H, L-leucine-CH2CH(CH3)2), 0.92 (t, 3H,
C19−H), 0.85 (m, 6H, L-leucine−CH(CH3)2); 13C NMR (100 MHz,
CDCl3) δ: 170.6, 167.0, 159.3, 157.0, 152.1, 148.8, 146.6, 145.1, 143.3,
131.1, 131.0, 129.8, 129.6, 129.0, 128.3, 128.1, 128.0, 126.4, 126.3,
123.9, 142.1, 140.2, 119.9, 114.8, 96.2, 67.1, 55.2, 50.0, 42.1, 40.8, 38.6,
31.7, 24.8, 22.6, 21.5, 7.5. HRMS calcd for C42H42N4O8S: 763.2796
[M + H]+; found, 763.2776 [M + H]+.
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Compound 9h. Yield 48%; mp 125−127 °C; tR-HPLC, 3.82 min
(97.0%). IR (KBr) ν cm−1: 3391, 3238, 2955, 1754, 1664, 1603, 1542,
1498, 1402, 1279, 1235, 1143, 1086, 1040, 810, 693; 1H NMR
(CDCl3, 400 MHz) δ 8.39 (s, 1H, C7−H), 8.29 (d, 1H, J = 8.4 Hz,
C9−H), 7.93 (d, 1H, J = 8.0 Hz, C12−H), 7.83 (t, 1H, C11−H), 7.76
(d, 2H, J = 8.4 Hz, Ts-H), 7.66 (t, 1H, C10−H), 7.36 (s, 1H, C14−
H), 7.25−7.20 (m, 3H, Ts-H, Ph-H), 7.14−7.12 (m, 4H, Ph-H), 5.48
(ABq, 2H, J = 17.2 Hz,C17−H), 5.26 (s, 2H, C5−H), 4.88 (m,
1H,C23−H), 4.03−4.36 (m, 2H, C30−H), 2.34 (s, 3H, Ts-CH3),
2.11−2.21 (m, 2H, C18−H), 1.56−1.79 (m, 2H, L-leucine-CH2CH-
(CH3)2), 1.48 (m, 1H, L-leucine-CH(CH3)2), 0.93 (m, 3H, C19−H),
0.83−0.93 (m, 6H, L-leucine−CH(CH3)2); 13C NMR (100 MHz,
CDCl3) δ 170.6, 166.9, 166.3, 157.3, 152.1, 148.8, 146.6, 145.1, 132.5,
131.0, 130.0, 129.8, 129.6, 129.4, 129.0, 128.3, 128.1, 128.0, 126.4,
140.3, 120.1,96.1, 67.2, 52.3, 50.0, 42.1, 40.8, 39.5, 31.7, 24.8, 22.8,
21.5, 7.5. HRMS calcd for C41H40N4O7S: 733.2690 [M + H]
+; found,
733.2670[M + H]+.
Compound 9i. Yield 58%; mp 127−129 °C; tR-HPLC, 4.95 min
(95.2%). IR(KBr) ν cm−1: 3339, 3259, 2932, 1752, 1666, 1617, 1514,
1459, 1402, 1279, 1250, 1140, 1085, 1038, 896, 753, 677, 553; 1H
NMR (CDCl3, 400 MHz) δ 8.38 (s, 1H, C7−H), 8.19 (d, 1H, J = 8.4
Hz, C9−H), 7.94 (d, 1H, J = 8.4 Hz, C12−H), 7.81 (t, 1H, C11−H),
7.74 (d, 2H, J = 8.0 Hz, Ts-H), 7.68 (t, 1H, J = 8.0 Hz, C10−H), 7.40
(d, 2H, J = 8.4 Hz, -PhOCH3), 7.36 (s, 1H, C14−H), 7.17 (d, 2H, J =
8.0 Hz, Ts-H), 7.03(d, 2H, J = 8.8 Hz, -PhOCH3), 5.50 (ABq, 2H, J =
17.2 Hz,C17−H), 5.26 (s, 2H, C5−H), 4.66 (m, 1H, C23−H), 4.33
(s, 2H, C30−H), 3.73 (s, 3H, -PhOCH3), 2.39 (s, 3H, Ts-CH3), 2.11−
2.21 (m, 2H, C18−H), 1.92−1.98 (m, 1H, L-isoleucine-CH(CH3)-
CH2CH3), 0.78−1.26 (m, 11H,C19−H, L-isoleucine-H); 13C NMR
(100 MHz, CDCl3) δ 168.2, 166.6, 166.4, 159.6, 157.2, 152.1, 148.9,
146.7, 144.8, 131.7, 131.0, 129.7, 129.6, 129.0, 128.3, 128.2, 128.0,
126.4, 124.6, 142.4, 140.2, 120.8, 115.1, 95.5, 67.5, 58.3, 55.3, 50.1,
42.1, 38.9, 37.9, 31.8, 24.9, 21.5, 15.0, 11.3, 7.4. HRMS calcd for
C42H42N4O8S: 763.2796 [M + H]
+; found, 763.2788 [M + H]+.
Compound 9j. Yield 54%; mp 125−127 °C; tR-HPLC, 3.72 min
(96.2%). IR (KBr) ν cm−1: 3339, 3258, 2966, 1751, 1666, 1619, 1539,
1454, 1401, 1280, 1258, 1142, 1085, 1051, 989, 693, 553; 1H NMR
(CDCl3, 400 MHz) δ 8.38 (s, 1H, C7−H), 8.20 (d, 1H, J = 8.8 Hz,
C12−H), 7.94 (d, 1H, J = 8.0 Hz, C9−H), 7.81 (t, 1H, C11−H), 7.75
(d, 2H, J = 8.0 Hz, Ts-H), 7.67 (t, 1H, C10−H), 7.50 (m, 4H,Ts, Ph-
H), 7.37 (s, 1H, C14−H), 7.18 (d, 2H, J = 8.0 Hz, Ph-H), 7.00 (s, 1H,
Ph-H), 5.51 (ABq, 2H, J = 17.6 Hz, C17−H), 5.26 (s, 2H, C5−H),
4.66 (m, 1H, C23−H), 4.40 (s, 2H, C30−H), 2.37 (s, 3H, Ts-CH3),
1.90−2.23 (m, 3H, C18−H, L-isoleucine-CH(CH3)CH2CH3), 1.14
(m, 2H, L-isoleucine−CH(CH3)CH2CH3), 0.78−0.86 (m, 9H, C19−
H, L-isoleucine−CH(CH3)CH2CH3); 13C NMR (100 MHz,CDCl3) δ
168.2, 166.6, 166.0, 157.2, 152.2, 148.9, 146.7, 144.0, 133.0, 131.0,
130.6, 130.4, 129.8, 129.0,128.4, 128.3, 128.2, 128.1, 126.2, 142.2,
140.3, 120.9, 95.5, 67.4, 50.1, 42.2, 39.7, 37.4, 31.8, 24.9, 21.4, 15.0,
11.3, 7.4. HRMS calcd for C41H40N4O7S: 733.2690 [M + H]
+; found,
733.2669 [M + H]+.
Compound 9k. Yield 52%; m.p.102−104 °C; tR-HPLC, 5.36 min
(96.4%). IR (KBr) ν cm−1: 3385, 3262, 2929, 1750, 1663, 1611, 1544,
1451, 1280, 1246, 1144, 1048, 812, 757, 693, 552; 1H NMR (CDCl3,
400 MHz) δ 8.39 (s, 1H, C7−H), 8.22 (d, 1H, J = 8.4 Hz, C9−H),
7.95 (d, 1H, J = 8.0 Hz, C12−H), 7.82 (m, 3H, C11−H, Ts-H), 7.67
(t, 1H, C10−H), 7.36 (s, 1H, C14−H), 7.21 (d, 2H, J = 8.0 Hz, Ts-
H), 7.17−7.15 (m, 3H, L-phenylalanine-Ph), 7.10 (d, 2H, J = 8.4 Hz,
-PhOCH3), 6.99−7.02 (m, 2H, L-phenylalanine-Ph), 6.89 (d, 2H, J =
8.8 Hz, -PhOCH3), 5.50 (ABq, 2H, J = 17.2 Hz, C17−H), 5.26 (s, 2H,
C5−H), 4.91 (m, 1H, C23−H), 4.23 (s, 2H, C30−H), 3.78 (s, 3H,
-PhOCH3), 3.12−3.06 (m, 2H, L-phenylalanine-CH2), 2.39 (s, 3H, Ts-
CH3), 2.11−2.21 (m, 2H, C18−H), 0.81 (m, 3H, C19−H); 13C NMR
(100 MHz, CDCl3) δ 169.0, 166.7, 166.4, 159.4, 157.2, 152.2, 148.9,
146.2, 144.3, 134.8, 131.5, 131.0, 129.8, 129.4, 129.1, 128.6, 128.4,
128.2, 128.1, 127.2, 126.4,124.0, 142.2, 140.3, 120.5, 114.9, 95.9, 67.2,
55.3, 54.9, 50.1, 38.7, 36.6, 32.0, 21.4, 7.4. HRMS calcd for
C45H40N4O8S: 797.2640 [M + H]
+; found, 797.2661 [M + H]+.
Compound 9l. Yield 35%; mp 123−125 °C; tR-HPLC, 3.20 min
(100%). IR (KBr) ν cm−1: 3419, 3269, 2925, 1751, 1644, 1601, 1540,
1401, 1277, 1236, 1139, 1087, 1050, 814, 758, 699, 552; 1H NMR
(CDCl3, 400 MHz) δ 8.45 (s, 1H, C7−H), 8.13 (d, 1H, J = 8.4 Hz,
C9−H), 7.97 (d, 1H, J = 8.0 Hz, C12−H), 7.87 (t, 1H, C11−H), 7.71
(t, 1H, C10−H), 7.65 (d, 2H, J = 8.4 Hz, Ts-H), 7.36 (s, 1H, C14−
H), 7.22 (d, 2H, J = 8.0 Hz, Ts-H), 7.17−7.20 (m, 5H, L-
phenylalanine-Ph), 5.52 (ABq, 2H, J = 17.2 Hz, C17−H), 5.26 (s,
2H, C5−H), 4.91(m, 1H, C-23H), 4.11 (m, 2H, -CH2OH), 3.14−3.23
(m, 2H, L-phenylalanine-CH2), 2.39 (s, 3H, Ts-CH3), 2.11−2.21 (m,
2H, C18−H), 0.91 (m, 3H, C19−H); 13C NMR (100 MHz, CDCl3) δ
167.7, 166.6, 166.5, 157.1, 152.1, 148.1, 145.8, 144.4, 135.1, 132.1,
131.3, 129.5, 129.4, 129.1, 129.0, 128.8, 128.5, 128.4, 128.3, 127.2,
126.4, 140.2, 121.0, 96.4, 67.2, 58.9, 56.1, 50.1, 37.5, 35.6, 32.0, 21.4,
7.5. HRMS calcd for C39H36N4O8S 743.2146 [M + Na]
+; found,
743.2158 [M + Na]+.
Cell Lines and Cytotoxicity Assay. The human tumor cell lines
used in this work were A-549 (lung carcinoma), DU-145 (hormone-
insensitive prostate cancer), KB (originally isolated from epidermoid
carcinoma of the nasopharynx), KBvin (vincristine-resistant KB
subline), and HCT116 (colorectal adenocarcinoma). These cell lines
were obtained from the Lineberger Comprehensive Cancer Center
(UNC-CH) or from ATCC (Manassas, VA), except KBvin, which was
a generous gift from Professor Y.-C. Cheng (Yale University). All cell
lines were maintained and assayed in RPMI-1640 medium containing
2 mM L-glutamine and 25 mM HEPES (HyClone), supplemented
with 10% heat-inactivated fetal bovine serum (HyClone), 100 μg/mL
streptomycin, 100 IU/mL penicillin, and 0.25 μg/mL amphotericin B
(Cellgro) in a humidified atmosphere containing 5% CO2 in air.
Compound stock solutions were prepared at 10 mM in DMSO and
diluted with culture medium with the final DMSO concentration
≤0.01% (v/v), a concentration without effect on cell growth. The 4−6
× 103 cells/well were cultured for 72 h with various concentrations of
test compounds in 96-well plates at 37 °C. The antiproliferative
activities of compounds were determined by a sulforhodamine B assay
according to the procedures developed and validated at NCI30 and are
expressed as IC50 (μM) values, which reduced the cell number by 50%
compared with that of the vehicle control after 72 h of continuous
treatment. Each assay was performed in triplicate with duplicated
samples.
Morphological Observation. Morphological changes of culture
cells were observed under a phase contrast microscope and
photographed with a digital camera (Nikon, Japan).
Apoptosis Assessment. Apoptosis was detected by an Annexin
V-FITC/propidium iodide double staining kit (BD Biosciences). A-
549 cells were treated with 9a for 24 or 48 h. Cells were harvested by
trypsinization and washed with ice-cold PBS. Cells were labeled with
annexin V-FITC and propidium iodide for 15 min at room
temperature in the dark. Labeled cells were analyzed by an
FACSCalibur flow cytometer (Becton Dickinson).
Cell Cycle Analysis. A-549 cells were fixed with ice-cold 70%
EtOH followed by propidium iodide staining. Samples were analyzed
by a flow cytometer for cell cycle determination. Population of each
cell cycle phase was calculated based on the ploidy (<2N as sub-G1;
2N as G1; between 2N and 4N as S; and 4N as G2/M) and evaluated
statistically by Student’s t-test (P < 0.01).
Western Blot Analysis. Cells were harvested in PBS containing
proteinase inhibitors and phosphatase inhibitors, and sonicated. Whole
cell lysates were separated by SDS−PAGE and transferred to
Immobilon P membrane (EMD Millipore). The membrane was
incubated with primary antibody followed by labeling with horseradish
peroxidase (HRP)-conjugated secondary antibody (EMD Millipore).
A chemilluminence substrate kit (EMD Millipore) was used for the
detection of membrane-bound HRP and visualized by a luminsence
image analyzer, LAS4000 (Fuji Photo Film Co., Japan).
Antibodies. Antibodies to caspase-3, caspase-8, caspase-9, PARP,
phospho-ATM (Ser1981), ATM, phospho-ATR (Ser428), phospho-
Chk1 (Ser345), phospho-Chk2 (Thr68), Chk2, phospho-H2AX
(Ser139), and phospho-p53 (Ser15) were purchased from Cell
Signaling Technology. Antibodies against ATM, ATR, Chk1, and
PUMA were from Santa Cruz Biotechnology. Antibodies against Topo
I, Topo IIα, Topo IIβ, p53, FADD, BAX, Bcl-xL, and Bcl-2 were from
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BD Biosciences. Antibody to β-actin was purchased from EMD
Millipore.
Topoisomerase I Activity Assay in a Cell-Free System. One
unit of recombinant human topoisomerase I enzyme (TopoGEN) was
preincubated for 20 min at 37 °C with vehicle, 9a, 1, 3, or SN-38 in a
final volume of 20 μL of reaction buffer (10 mM Tris-HCl, pH 7.9, 1
mM EDTA, 150 mM NaCl, 0.1% BSA, 0.1 mM spermidine, and 5%
glycerol) was then incubated with 250 ng of supercoiled plasmid DNA
for 20 min. The supercoiled, relaxed, or nicked DNA was separated by
1% agarose gel in 1× TAE (Tris-Acetate-EDTA) buffer. Ethidium
bromide stained agarose gel was photographed using Gel Doc XR
(Bio-Rad).
Topoisomerase I Activity Assay. The Topo I activity test was
performed using an assay kit (TopoGEN) according to the
manufacturer’s instructions. Nuclear extracts from 9a-treated A-549
cells were incubated with supercoiled DNA (for Topo I) or catenated
kDNA (for Topo II) for 30 min at 37 °C. The reaction mixture was
separated by 1% agarose gel in 1× TAE buffer. The gel was stained
with ethidium bromide and photographed using Gel Doc XR (Bio-
Rad).
Xenograft Model Antitumor Assay. Five- to six-week-old female
nu/nu mice (National Laboratory Animal Center, Taiwan) were
inoculated subcutaneously with 2 × 106 human colorectal
adenocarcinoma HCT116 cells in the flank. When the grafted tumor
volume reached the average volume of 200 mm3, mice were randomly
divided into four groups (n = 8). The treatment regimen is shown in
Table 2. Vehicle control and compound 9a at 5 or 10 mg/kg were
administered i.v. once a day (QD) for 7 days and then i.p. once a day
to the end. As an experimental control group, 100 mg/kg of
compound 3 was administered i.v. once a week (QWK) to the end.
The length (L) and width (W) of the graft was measured every 3 to 4
days to the end, and the tumor volume was calculated as LW2/2.
Results were evaluated statistically by Student’s t-test. This study was
approved by the Institutional Animal Care and Use Committee
(IACUC) of the National Taiwan University (Taipei, Taiwan) and was
performed according to the institutional guidelines.
Pathological Evaluation of in Vivo Toxicity. Sixty 8-week-old
male BALB/c mice (National Laboratory Animal Center, Taipei,
Taiwan) were used to evaluate single-dose toxicity. Mice were
randomly divided into six groups (n = 10) and received a single i.p.
injection of 9a at 0 (vehicle), 30, 100, 200, or 300 mg/kg on day 0.
One group was untreated as the normal control. Body weight was
measured every 3 days for 15 days. At the end of experimental period,
all animals were euthanized by CO2, and tissues from the liver, lung,
kidney, and spleen were weighed (data not shown). Tissues were fixed
with 10% formalin and embedded in paraffin. Sections 3−5 μm in
thickness were prepared for histopathological examination. Hematox-
ylin and eosin (H&E) stained paraffin sections were evaluated
histopathologically according to the guideline described by Shackelford
et al.,36 and the symptomatic lesions were graded. The degree of
lesions were graded from one to five depending on severity as follows:
nothing significant, 1 = minimal (<1%), 2 = slight (1−25%), 3 =
moderate (26−50%), 4 = moderately severe (51−75%), and 5 =
severe/high (76−100%). Statistically significant results (P < 0.05)
were shown. This study was approved by the Institutional Animal Care
and Use Committee (IACUC) of China Medical University




HPLC results and conditions for 9a−9l. This material is
available free of charge via the Internet at http://pubs.acs.org.
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